NEW YORK (GenomeWeb) – Goldfinch Bio announced today that it has partnered with the the Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to generate genomic data on over 1,500 patients with proteinuric kidney disease.
Under the terms of the deal, the partners will integrate genomic analyses and de-identified clinical data from Mount Sinai's BioMe BioBank and Vanderbilt's BioVU BioBank into Goldfinch's genomic registry of kidney disease patients. The company is building the registry to support the identification of disease targets, pathways, and biomarkers for novel drug discovery and development.
Additional terms were not disclosed.
"We are thrilled to work with the Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to advance our understanding of the molecular pathways of kidney disease and bring precision medicines to patients," Goldfinch Interim CEO Abbie Celniker said in a statement.
Goldfinch launched in late 2016 with $55 million in Series A funding with an initial focus on orphan kidney diseases with genetic bases. Earlier this month, the firm partnered with the with the Nephrotic Syndrome Study Network to generate and analyze genomic and transcriptomic data on over 1,000 samples from proteinuric kidney disorder patients.